Richard V. Parry

5.9k citations

32 papers · 4.6k indexed · 3 hit papers · h-index 23

Immunology top 0.5%
Oncology top 1%
Molecular Biology top 5%
Cancer Research top 5%
Epidemiology top 10%

Co-authors: James L. Riley Jens M. Chemnitz Carl H. June Kenneth A. Frauwirth Craig B. Thompson Kim E. Nichols Sumire Kobayashi Inbal Braunstein
Topics: T-cell and B-cell Immunology (12 papers)Immune Cell Function and Interaction (11 papers)PI3K/AKT/mTOR signaling in cancer (9 papers)
Cited by: Immunology Oncology Cancer Research
Journals: Journal of Biological Chemistry Blood Immunity
Partner nations: United Kingdom United States France

In The Last Decade

Richard V. Parry

31 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

2005 1.5k citations Richard V. Parry, Jens M. Chemnitz et al. Molecular and Cellular Biology profile →
The CD28 Signaling Pathway Regulates Glucose Metabolism

2002 1.1k citations Kenneth A. Frauwirth, James L. Riley et al. Immunity profile →
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation

2004 927 citations Jens M. Chemnitz, Richard V. Parry et al. The Journal of Immunology profile →

Peers

Countries citing papers authored by Richard V. Parry

Since Specialization

Citations

This map shows the geographic impact of Richard V. Parry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard V. Parry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard V. Parry more than expected).

Fields of papers citing papers by Richard V. Parry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard V. Parry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard V. Parry. The network helps show where Richard V. Parry may publish in the future.

Co-authorship network of co-authors of Richard V. Parry

This figure shows the co-authorship network connecting the top 25 collaborators of Richard V. Parry. A scholar is included among the top collaborators of Richard V. Parry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard V. Parry. Richard V. Parry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Growth capacity of a Wharton’s Jelly derived mesenchymal stromal cells tissue engineered vascular graft used for main pulmonary artery reconstruction in piglets 2024 ·Frontiers in Bioengineering and Biotechnology ·Dominga Iacobazzi,Mohamed Ghorbel,Filippo Rapetto,(unknown),Julia Deutsch,(unknown),(unknown),Katie L. Skeffington,Richard V. Parry,(unknown),Guillaume Chanoit,Massimo Caputo	0
2	High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment 2020 ·Cancer Research ·Lissete Sánchez‐Magraner,(unknown),(unknown),(unknown),Dae‐Jin Lee,Somaia Elsheikh,(unknown),(unknown),Andrew G. Watts,Richard V. Parry,Christine Edmead,José I. López,Raj Mehta,Antoîne Italiano,Stephen G. Ward,Peter J. Parker,Banafshé Larijani	26
3	Protein arginine methylation: a new handle on T lymphocytes? 2010 ·Trends in Immunology ·Richard V. Parry,Stephen G. Ward	32
4	Toward the development of potent and selective bisubstrate inhibitors of protein arginine methyltransferases 2010 ·Bioorganic & Medicinal Chemistry Letters ·James Dowden,Wei Hong,Richard V. Parry,(unknown),Stephen G. Ward	58
5	Genetic engineering of T cells for adoptive immunotherapy 2008 ·Immunologic Research ·Angel Varela‐Rohena,Carmine Carpenito,Elena Pérez,Max W. Richardson,Richard V. Parry,Michael C. Milone,John Scholler,Xueli Hao,Angela M. Mexas,Richard G. Carroll,Carl H. June,James L. Riley	51
6	Phosphoinositide Lipid Phosphatases: Natural Regulators of Phosphoinositide 3-Kinase Signaling in T Lymphocytes 2007 ·Journal of Biological Chemistry ·(unknown),Richard V. Parry,John Westwick,Stephen G. Ward	54
7	Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation 2007 ·Trends in Immunology ·Richard V. Parry,James L. Riley,Stephen G. Ward	26
8	Ligation of CD28 Stimulates the Formation of a Multimeric Signaling Complex Involving Grb-2-Associated Binder 2 (Gab2), Src Homology Phosphatase-2, and Phosphatidylinositol 3-Kinase: Evidence That Negative Regulation of CD28 Signaling Requires the Gab2 Pleckstrin Homology Domain 2006 ·The Journal of Immunology ·Richard V. Parry,(unknown),Martin Sims,Christine Edmead,Melanie J. Welham,Stephen G. Ward	20
9	Evidence that phospholipase C-dependent, calcium-independent mechanisms are required for directional migration of T lymphocytes in response to the CCR4 ligands CCL17 and CCL22 2006 ·Journal of Leukocyte Biology ·Darran G. Cronshaw,(unknown),Richard V. Parry,(unknown),Zarin Brown,Stephen G. Ward	38
10	CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanismsbreakdown → 2005 ·Molecular and Cellular Biology ·Richard V. Parry,Jens M. Chemnitz,Kenneth A. Frauwirth,Anthony R. Lanfranco,Inbal Braunstein,Sumire Kobayashi,Peter S. Linsley,Craig B. Thompson,James L. Riley	1541
11	Ligation of CD28 by Its Natural Ligand CD86 in the Absence of TCR Stimulation Induces Lipid Raft Polarization in Human CD4 T Cells 2005 ·The Journal of Immunology ·Birgit Kovacs,Richard V. Parry,Zhengyu Ma,(unknown),Debra K. Shivers,Benjamin A. Freiberg,Anna Thomas,(unknown),Catherine A. Rumbley,James L. Riley,Terri H. Finkel	29
12	SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activationbreakdown → 2004 ·The Journal of Immunology ·Jens M. Chemnitz,Richard V. Parry,Kim E. Nichols,Carl H. June,James L. Riley	927
13	CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes 2003 ·The Journal of Immunology ·Richard V. Parry,Catherine A. Rumbley,Luk H. Vandenberghe,Carl H. June,James L. Riley	131
14	The CD28 Signaling Pathway Regulates Glucose Metabolismbreakdown → 2002 ·Immunity ·Kenneth A. Frauwirth,James L. Riley,Marian H. Harris,Richard V. Parry,Jeffrey C. Rathmell,David R. Plas,Rebecca Elstrom,Carl H. June,Craig B. Thompson	1134
15	CD28 stimulates tyrosine phosphorylation, cellular redistribution and catalytic activity of the inositol lipid 5-phosphatase SHIP 1999 ·European Journal of Immunology ·(unknown),Richard V. Parry,Steven Burgess,Barbara J. Reaves,Stephen G. Ward	30
16	Ligation of the T cell co‐stimulatory receptor CD28 activates the serine‐threonine protein kinase protein kinase B 1997 ·European Journal of Immunology ·Richard V. Parry,Karin Reif,(unknown),David M. Sansom,Brian A. Hemmings,Stephen G. Ward	105
17	45 Activation of the PI3K Effector Protein Kinase B Following Ligation of CD28 or Fas 1997 ·Biochemical Society Transactions ·Richard V. Parry,Graham A. Smith,Karin Reif,David M. Sansom,Stephen G. Ward	10
18	Inhibition of sperm-zona binding by suramin, a potential ‘lead’ compound for design of new anti-fertility agents 1996 ·Molecular Human Reproduction ·Roy Jones,Richard V. Parry,Leila Lo Leggio,Peter Nickel	23
19	Antibody ligation of CD7 leads to association with phosphoinositide 3‐kinase and phosphatidylinositol 3,4,5‐trisphosphate formation in T lymphocytes 1995 ·European Journal of Immunology ·Stephen G. Ward,Richard V. Parry,(unknown),David M. Sansom,John Westwick,Andrew I. Lazarovits	24
20	Characterization of low Mr Zona Pellucida binding proteins from boar spermatozoa and seminal plasma 1992 ·Molecular Reproduction and Development ·Richard V. Parry,P. J. Barker,Roy Jones	29

About Richard V. Parry

Richard V. Parry is a scholar working on Immunology, Genetics and Toxicology, having authored 32 papers that have together received 4.6k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (12 papers), Immune Cell Function and Interaction (11 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). The work is most often cited by research in Immunology (3.0k citations), Oncology (2.2k citations) and Cancer Research (440 citations). Richard V. Parry has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include James L. Riley, Jens M. Chemnitz, Carl H. June, Kenneth A. Frauwirth, Craig B. Thompson, Kim E. Nichols, Sumire Kobayashi, Inbal Braunstein, Peter S. Linsley and Anthony R. Lanfranco. Their work appears in journals such as Journal of Biological Chemistry, Blood and Immunity.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact